ABBV vs JNJ
ABBV and JNJ side by side — valuation & fundamentals (public data).
Key statistics
| Metric | ABBVAbbVie Inc. | JNJJohnson & Johnson |
|---|---|---|
| Market cap | $459.89B | $649.78B |
| P/E (TTM) | 73.5 | 31.3 |
| P/B | — | 7.65 |
| P/S | 7.4x | 6.8x |
| Dividend yield | 2.53% | 1.91% |
| Revenue | $61.16B(TTM) | $97.93B(TTM) |
| Revenue growth (YoY) | 8.6% | 6.0% |
| Net income | $6.31B(TTM) | $21.04B(TTM) |
| Earnings growth (YoY) | -1.2% | 90.6% |
| EPS, diluted | $3.54(TTM) | $8.62(TTM) |
| EBIT margin | 24.6% | 22.9% |
| ROE | — | 31.5% |
| ROIC | 18.6% | 16.1% |
| Piotroski F | — | 6/9 |
| 1y total return | +25.1% | +52.9% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: ABBV vs JNJ
| Metric | ABBV | JNJ |
|---|---|---|
| End value | $64.9K | $32.0K |
| Total return | +549.5% | +220.1% |
| CAGR | +19.8% | +11.9% |
| Volatility | 25.9% | 18.6% |
| Sharpe | 0.68 | 0.49 |
| Sortino | 0.95 | 0.70 |
| Max drawdown | -45.1% | -27.4% |
Based on 2600 common trading days, 2016-04-29 → 2026-09-01 · risk-free 3.91% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)